These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 33508242)

  • 1. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
    Kawazoe A; Ando T; Hosaka H; Fujita J; Koeda K; Nishikawa K; Amagai K; Fujitani K; Ogata K; Watanabe K; Yamamoto Y; Shitara K
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):209-217. PubMed ID: 33508242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Alsina M; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Hosokawa A; Yalçın Ş; Fujitani K; Beretta GD; Cutsem EV; Winkler RE; Makris L; Ilson DH; Tabernero J
    Lancet Oncol; 2018 Nov; 19(11):1437-1448. PubMed ID: 30355453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study.
    Narita Y; Ogata T; Ishizuka Y; Sakakida T; Wakabayashi M; Kodama H; Honda K; Masuishi T; Taniguchi H; Kadowaki S; Ando M; Tajika M; Muro K
    Sci Rep; 2024 Jun; 14(1):12658. PubMed ID: 38830895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
    Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
    Takahashi N; Hara H; Nagashima K; Hirata K; Masuishi T; Matsumoto T; Kawakami H; Yamazaki K; Hironaka S; Boku N; Muro K
    BMC Cancer; 2023 Aug; 23(1):726. PubMed ID: 37543568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
    Nakanishi K; Tanaka C; Kanda M; Miyata K; Machida N; Sakai M; Kobayashi D; Teramoto H; Ishiyama A; Sato B; Oshima T; Kajikawa M; Matsushita H; Ishigure K; Yamashita K; Fujitake S; Sueoka S; Asada T; Shimizu D; Sugita S; Kuwatsuka Y; Maeda O; Furune S; Murotani K; Ando Y; Ebata T; Kodera Y
    Nagoya J Med Sci; 2024 Feb; 86(1):43-51. PubMed ID: 38505718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
    Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA;
    Lancet Oncol; 2019 Mar; 20(3):420-435. PubMed ID: 30718072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).
    Shitara K; George B; Taieb J; Sundar R; Fakih MG; Makris L; Benhadji KA; Ghidini M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9361-9374. PubMed ID: 37213030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.
    Cleary JM; Rosen LS; Yoshida K; Rasco D; Shapiro GI; Sun W
    Invest New Drugs; 2017 Apr; 35(2):189-197. PubMed ID: 28111727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers.
    Takahashi M; Sakamoto Y; Ohori H; Tsuji Y; Kuroki M; Kato S; Otsuka K; Komine K; Takahashi M; Takahashi S; Shirota H; Ouchi K; Takahashi Y; Imai H; Shibata H; Yoshioka T; Tanaka M; Yamaguchi H; Yamaguchi T; Shimodaira H; Ishioka C
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):393-402. PubMed ID: 34028598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
    Saif MW; Becerra CR; Fakih MG; Sun W; Popovic L; Krishnamurthi S; George TJ; Rudek MA; Shepard DR; Skopek J; Sramek V; Zaric B; Yamamiya I; Benhadji KA; Hamada K; He Y; Rosen L
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):485-497. PubMed ID: 34097100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
    Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
    Okunaka M; Kawazoe A; Nakamura H; Kotani D; Mishima S; Kuboki Y; Nakamura Y; Shitara K
    Gastric Cancer; 2023 Nov; 26(6):1030-1039. PubMed ID: 37665515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer.
    Yoshino T; Uetake H; Funato Y; Yamaguchi Y; Koyama T; Ozawa D; Tajiri M; Muro K
    Jpn J Clin Oncol; 2021 Apr; 51(5):700-706. PubMed ID: 33438718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
    Kuboki Y; Nishina T; Shinozaki E; Yamazaki K; Shitara K; Okamoto W; Kajiwara T; Matsumoto T; Tsushima T; Mochizuki N; Nomura S; Doi T; Sato A; Ohtsu A; Yoshino T
    Lancet Oncol; 2017 Sep; 18(9):1172-1181. PubMed ID: 28760399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment.
    Niisato Y; Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Shimada Y
    Anticancer Res; 2021 Apr; 41(4):2203-2207. PubMed ID: 33813435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
    André T; Falcone A; Shparyk Y; Moiseenko F; Polo-Marques E; Csöszi T; Campos-Bragagnoli A; Liposits G; Chmielowska E; Aubel P; Martín L; Fougeray R; Amellal N; Saunders MP
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):133-144. PubMed ID: 36470291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.